M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Chelsea Therapeutics International Ltd wins FDA accelerated approval of NORTHERA (Droxidopa) for treating symptomatic NOH
Biopharmaceutical company Chelsea Therapeutics International Ltd (NasdaqCM:CHTP) reported on Tuesday the receipt of accelerated approval from the US Food and Drug Administration (FDA) for NORTHERA, the company's therapy for the treatment of symptomatic neurogenic orthostatic hypotension (NOH)....
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives